Heartbeam (BEAT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
25 Jun, 2026Executive summary
Supplement details changes to board nominees for the 2026 Annual Meeting scheduled for July 31, 2026.
Two nominees, Mark Strome and Rob Eno, have withdrawn from re-election due to resignation and mutual agreement, respectively.
No replacement nominees will be named for the withdrawn candidates.
Voting matters and shareholder proposals
Shareholders who have already voted do not need to take action unless they wish to change their vote.
Proxies will remain valid, but votes will not be cast for the withdrawn nominees.
All other agenda items and voting instructions remain unaffected.
Board of directors and corporate governance
Mark Strome resigned from the board for personal reasons, effective June 18, 2026.
Rob Eno, CEO and board member, will depart as of June 30, 2026, as part of a strategic reorganization.
Both departures were not due to disputes or disagreements with company operations or policies.
Latest events from Heartbeam
- Lower Q3 losses and FDA milestones advance heart-attack assessment, but funding risks remain.BEAT
Q3 2026 - Commercial launch is underway as clinical studies advance a broader cardiac platform opportunity.BEAT
Investor presentation - Clinical and commercial progress accelerated, cash runway extended, but liquidity risks remain.BEAT
Q2 2026 - Directors and auditor approved; equity plan amendment failed; updates set for August.BEAT
AGM 2026 - Annual meeting to elect directors, ratify auditor, and expand equity plan by 3 million shares.BEAT
Proxy filing - FDA-cleared at-home 12-lead ECG platform targets $40B market with scalable, AI-driven growth.BEAT
Investor presentation - Annual meeting to elect directors, ratify auditor, and expand equity plan by 3 million shares.BEAT
Proxy filing - Net loss narrowed, cash burn fell, and $11.5M funding supports clinical and commercial growth.BEAT
Q1 2026 - AIMIGo nears FDA clearance as Q2 loss hits $5M, cash burn raises going concern risk.BEAT
Q2 2024